TiGenix snags $13.7M for Phase III cell therapy

Damian Garde

Belgium's has hauled in about $ 13.7 million in debt financing, piling up cash as it works through III with a stem treatment.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS